SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses potential price movements and upcoming catalysts, like a possible Solana ETF. Community members are focused on phrases like "WAGMI" and speculate on $200+ targets. There's also discussion around various Solana-based meme coins gaining traction.

Pump.fun

$PUMP is trending amid community enthusiasm and the popular 'WAGMI' (We're All Gonna Make It) mantra, with many highlighting its potential within the Solana ecosystem. Discussions revolve around its strong community, recognizable branding, and the belief that it's coded for significant growth. The community views $PUMP as more than just a ticker, but a mission statement.

Trump For President

The Trump Crypto token is trending amidst community discussions around its performance and potential connection to political events. Some traders are expressing concerns about its volatility, while others are speculating on future growth tied to Trump's political activity; overall sentiment appears mixed, with some users calling it a 'scam coin'.

WorldFinancial

WLFI is trending as community members discuss its connection to $TRUMP and potential for real-world asset tokenization. Speculation is fueled by potential partnerships and product launches like the USD1 stablecoin and a debit card. Community chatter also focuses on market manipulation, short squeezes, and the impact of regulatory clarity.

Shibmas was launched on the 9th Of December. The project is a meme token and gives homage to Shiba Inu the token. The token is a playful character who is bringing the Christmas spirit to token holders all around the world. We plan on getting many listings on various exchanges in the coming days. We have over 1000 holders in 24 hours and we aim on getting over 10000 holders within the next week and in the run up to Christmas

Shibmas

Shibmas ($SMAS) is trending amid community excitement and positive sentiment, particularly within the Phantom Wallet ecosystem. Discussions highlight its clean chart, potential for a breakout, and steady price action, with many noting the 'bullish vibes' and 'rocket energy' surrounding the crypto. The community is closely watching for increased volume and a catalyst to propel the price higher.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members express strong conviction in its long-term potential within the Solana ecosystem. Discussions highlight its resilient market capitalization, growing holder base, and potential for significant revaluation as part of the cultural finance movement on Solana. The community emphasizes that "We're All Gonna Make It" is more than just a meme, but a core principle.

First Citizens BancShares, Inc. is a bank holding company, which provides retail and commercial banking services through its subsidiaries. The company operates under the following segments: General Banking, Commercial Banking, Rail, and Corporate. The General Banking delivers services to individuals through branch networks. The Commercial Banking provides lending, leasing and other financial and advisory services to small and middle market companies. The Rail segment deals with the provision of equipment leasing and secured financing for railroads and shippers. The Corporate segment is comprised of investment securities and interest bearing cash. The company was founded on August 7, 1986 and is headquartered in Raleigh, NC.

First Citizens Bancshares, Inc (NC) - Ordinary Shares - Class A

Fueled by the acquisition of Silicon Valley Bank assets, First Citizens Bancshares is trending as the community debates the long-term implications of the deal. Some traders point to potentially overvalued conditions and prepare for a pullback, while others highlight positive analyst ratings and the bank's historical performance. Discussions also include the unusual market behavior, potential manipulation, and the impact of wider economic conditions on FCNCA.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Avidity Biosciences ($RNA) is trending amid rumors of a potential acquisition by Novartis, driving significant community discussion and a surge in stock price. Investors are closely watching upcoming conferences and data readouts, speculating on the likelihood of a buyout offer and its potential premium. The focus remains on Avidity's pipeline and its potential impact on the rare neuromuscular disease treatment landscape.

Citizens Financial Group, Inc. engages in the provision of commercial banking services. It operates through the Consumer Banking and Commercial Banking segments. The Consumer Banking segment includes deposit products, mortgage and home equity lending, student loans, auto financing, credit cards, business loans, and wealth management and investment services. The Commercial Banking segment offers lending and leasing, trade financing, deposit and treasury management, foreign exchange and interest rate risk management, corporate finance and debt, and equity capital markets. The company was founded in 1828 and is headquartered in Providence, RI.

Citizens Financial Group Inc

Citizens Financial Group is trending as the community discusses recent analyst rating adjustments and Q3 earnings expectations. Some are evaluating the bank's potential for growth, while others point to unusual options activity as a possible signal. The stock's dividend yield and recent news regarding share buybacks are also being highlighted.

LPL Financial Holdings, Inc. serves the advisor-mediated marketplace as the nation’s independent broker-dealer and is an investment advisory firm and a custodian. It offers integrated technology solutions, brokerage & advisory platforms, clearing, compliance, business and planning and advice services, consultative practice management programs and training. The company provides personalized financial guidance to millions of American families seeking wealth management, retirement planning, financial planning and asset management solutions. LPL Financial Holdings was founded in 1989 and is headquartered in San Diego, CA.

LPL Financial Holdings Inc

LPL Financial is trending amid analyst rating adjustments and target price changes, with community members focused on unusual options activity. Discussions also highlight asset growth and potential acquisitions impacting the financial advisor network. Community perspectives appear mixed, weighing bullish sentiment against potential vulnerabilities.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma PR Newswire PRINCETON, N.J...

Shares of Soligenix rallied sharply on Tuesday, marking their best performance in nearly two months, after the biopharmaceutical company reported a key safety milestone in its confirmatory Phase 3 FLASH2 trial evaluating HyBryte (synthetic hypericin) for treating cutaneous T-cell lymphoma (CTCL).The stock jumped 20% to $1.64 on Tuesday, and added another 0.9% after hours in continued upbeat trading.The company said its first Data Monitoring Committee (DMC) meeting for the study concluded that there were no safety concerns, with HyBryte’s safety profile consistent with prior trials.&nbsp;The committee’s conclusion allows the trial to move ahead as planned, with enrollment proceeding well and an update expected in the fourth quarter of 2025, followed by a blinded interim efficacy analysis in the first half of 2026.The ongoing FLASH2 trial is a randomized, double-blind, placebo-controlled, multicenter study enrolling about 80 patients with early-stage CTCL. The study builds on Soligenix’s previous successful Phase 3 FLASH trial, which showed a 49% treatment response after 18 weeks of therapy.&nbsp;FLASH2 extends continuous double-blind treatment to 18 weeks, designed to demonstrate the drug’s effect over a more “real-world” course.HyBryte, which uses visible light-activated synthetic hypericin applied topically to skin lesions, has received orphan drug and fast-track designations from the FDA, along with&nbsp;an orphan designation from the European Medicines Agency (EMA). The company stated that its light-activated mechanism enables deeper penetration into skin tissue without causing DNA damage, positioning it as a potentially safer frontline therapy for CTCL.On Stocktwits, retail sentiment for Soligenix was ‘extremely bullish’ amid a 2,025% surge in 24-hour message volume.One bullish user described the latest Soligenix update as a strong catalyst, saying the stock appeared ready to rebound sharply after the morning dip and could test new highs in the coming sessions.&nbsp;<stembedurl>https://stocktwits.com/LithiumMakesMeHard/message/631396013</stembedurl>Another bullish user noted that the price action suggested momentum might continue, with potential for a multiday run.<stembedurl>https://stocktwits.com/bzspy/message/631352248</stembedurl><a href="https://stocktwits.com/symbol/SNGX">Soligenix’s stock</a> has declined 39% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Soligenix’s stock (SNGX) has declined 39% so far in 2025. (Photo credit: Getty Images)

Soligenix Logs Best Session In Nearly 2 Months After Safety Win In T-Cell Lymphoma Trial — Traders Eye Multiday Rally

The company said enrollment in its Phase 3 HyBryte study is progressing well, with an interim efficacy analysis planned for the first half of 2026. 

Equity

Soligenix to Present at BIO CEO & Investor Conference

Soligenix to Present at BIO CEO & Investor Conference Soligenix to Present at BIO CEO & Investor Conference PR Newswire PRINCETON, N.J., Feb. 4, 2025 PRINCETON, N.J., Feb. 4, 2025 /PRNewswire...

Soligenix to Present at Upcoming Investor Conferences

Soligenix to Present at Upcoming Investor Conferences Soligenix to Present at Upcoming Investor Conferences PR Newswire PRINCETON, N.J., Jan. 16, 2025 PRINCETON, N.J., Jan. 16, 2025 /PRNewswire...

HyBryte Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

HyBryte Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma HyBryte Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage...

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment...

HyBryte Clinical Results Demonstrate Continued Improvement Post-Treatment

HyBryte Clinical Results Demonstrate Continued Improvement Post-Treatment HyBryte Clinical Results Demonstrate Continued Improvement Post-Treatment PR Newswire PRINCETON, N.J., Dec. 2, 2024...

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma PR...

Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels

Soligenix starts Phase 2 trial of SGX945 for Beh et's Disease, aiming to enroll 25 patients and report results by mid-2025. Trial includes efficacy assessments.
read more...

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin PR Newswire PRINCETON, N.J., Oct...

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Soligenix Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$1.58
Prev Close	$1.60
Open	$1.60
Dividend Yield	0.00%
50-Day Moving Average	$2.33
Beta	0.34
Avg. Volume	1.31M
PE Ratio	-0.41

52-Week High	$6.23
52-Week Low	$1.09
Market Capitalization	$15.58M
EPS (Annual)	-$4.98
Price to Book	3.03
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

SNGX
Soligenix Inc

Feed

News

Sentiment

Fundamentals

Info

Latest SNGX News

SNGXSoligenix Inc